Breaking News

Monday
Show Full Stories

X

To view all stories in expanded form, please subscribe.
Send Info
On The Fly
Fly Intel: After-Hours Movers » 18:53
10/19/20
10/19
18:53
10/19/20
18:53
CCK

Crown Holdings

$82.17 /

-1.115 (-1.34%)

, ZION

Zions Bancorp

$30.22 /

-0.92 (-2.95%)

, ELS

Equity Lifestyle

$63.05 /

-0.88 (-1.38%)

, APTX

Aptinyx

$3.64 /

-0.1 (-2.67%)

, ACOR

Acorda Therapeutics

$0.69 /

+0.0214 (+3.19%)

, IVA

Inventiva

$14.70 /

+0.41 (+2.87%)

, ATEC

Alphatec

$9.88 /

-0.23 (-2.27%)

, SPNE

SeaSpine

$14.97 /

-0.42 (-2.73%)

, HXL

Hexcel

$36.30 /

+0.73 (+2.05%)

, IBM

IBM

$125.53 /

-0.4 (-0.32%)

, PPG

PPG

$134.67 /

-2.555 (-1.86%)

, PHR

Phreesia

$32.30 /

-0.43 (-1.31%)

, BLU

Bellus Health

$2.32 /

-0.07 (-2.94%)

Check out this evening's…

ShowHide Related Items >><<
ZION Zions Bancorp
$30.22 /

-0.92 (-2.95%)

SPNE SeaSpine
$14.97 /

-0.42 (-2.73%)

PPG PPG
$134.67 /

-2.555 (-1.86%)

PHR Phreesia
$32.30 /

-0.43 (-1.31%)

IVA Inventiva
$14.70 /

+0.41 (+2.87%)

IBM IBM
$125.53 /

-0.4 (-0.32%)

HXL Hexcel
$36.30 /

+0.73 (+2.05%)

CCK Crown Holdings
$82.17 /

-1.115 (-1.34%)

BLU Bellus Health
$2.32 /

-0.07 (-2.94%)

ATEC Alphatec
$9.88 /

-0.23 (-2.27%)

APTX Aptinyx
$3.64 /

-0.1 (-2.67%)

ACOR Acorda Therapeutics
$0.69 /

+0.0214 (+3.19%)

CCK Crown Holdings
$82.17 /

-1.115 (-1.34%)

10/16/20 Credit Suisse
Crown Holdings assumed with an Outperform at Credit Suisse
10/14/20 Seaport Global
Crown Holdings initiated with a Buy at Seaport Global
10/07/20 Jefferies
Crown Holdings price target raised to $90 from $82 at Jefferies
09/18/20 JPMorgan
Crown Holdings price target raised to $85 from $81 at JPMorgan
ZION Zions Bancorp
$30.22 /

-0.92 (-2.95%)

09/29/20 Truist
Truist raises price targets on select regional banks
07/31/20 Wolfe Research
Zions Bancorp initiated with an Underperform at Wolfe Research
07/21/20 Truist
Zions Bancorp price target lowered to $40 from $50 at SunTrust
06/30/20 Truist
SunTrust raises price targets across regional/community banks
ELS Equity Lifestyle
$63.05 /

-0.88 (-1.38%)

10/01/20 BMO Capital
Sun Communities price target raised to $165 from $160 at BMO Capital
10/01/20 Berenberg
Equity Lifestyle initiated with a Buy at Berenberg
07/22/20 Baird
Equity Lifestyle upgraded to Outperform from Neutral at Baird
03/30/20 Evercore ISI
Equity Lifestyle upgraded to Outperform from In Line at Evercore ISI
APTX Aptinyx
$3.64 /

-0.1 (-2.67%)

10/14/20 JPMorgan
Aptinyx resumed with a Neutral at JPMorgan
07/01/20 Truist
Aptinyx initiated with a Buy at SunTrust
07/01/20 Truist
Aptinyx initiated with a Buy at SunTrust
05/08/20
Fly Intel: Top analyst initiations
ACOR Acorda Therapeutics
$0.69 /

+0.0214 (+3.19%)

10/24/19 JPMorgan
JPMorgan downgrades Acorda to Underweight on disappointing Inbrija launch
10/24/19 JPMorgan
Acorda Therapeutics downgraded to Underweight from Neutral at JPMorgan
IVA Inventiva
$14.70 /

+0.41 (+2.87%)

10/13/20 Roth Capital
Roth backs Buy on Inventiva after Lanifibranor given breakthrough designation
08/17/20 H.C. Wainwright
Inventiva price target raised to $38 from EUR 12 at H.C. Wainwright
08/05/20
Fly Intel: Top five analyst initiations
08/05/20 Roth Capital
Inventiva initiated with a Buy at Roth Capital
ATEC Alphatec
$9.88 /

-0.23 (-2.27%)

10/19/20 Stifel
Alphatec initiated with a Buy at Stifel
10/12/20 H.C. Wainwright
Alphatec price target raised to $12 from $9 at H.C. Wainwright
10/08/20 Lake Street
Alphatec price target raised to $15 from $13 at Lake Street
10/08/20 Canaccord
Alphatec price target raised to $12 from $9 at Canaccord
SPNE SeaSpine
$14.97 /

-0.42 (-2.73%)

10/19/20 Stifel
SeaSpine initiated with a Buy at Stifel
10/06/20 Piper Sandler
SeaSpine remains 'must-own SMID-cap name,' says Piper Sandler
08/05/20 Piper Sandler
SeaSpine remains 'must own SMID name' at Piper Sandler
06/16/20 Cantor Fitzgerald
SeaSpine assumed with an Overweight at Cantor Fitzgerald
HXL Hexcel
$36.30 /

+0.73 (+2.05%)

10/13/20 Wells Fargo
Hexcel price target lowered to $42 from $47 at Wells Fargo
10/09/20
Fly Intel: Top five analyst downgrades
10/09/20 Credit Suisse
Hexcel downgraded to Neutral from Outperform at Credit Suisse
09/25/20 Truist
Hexcel started with a Hold at Truist on commercial aero exposure
IBM IBM
$125.53 /

-0.4 (-0.32%)

10/09/20 Morgan Stanley
IBM price target raised to $140 from $128 at Morgan Stanley
09/22/20 UBS
IBM assumed with a Neutral at UBS
08/17/20 JPMorgan
IBM price target raised to $148 from $135 at JPMorgan
07/22/20 Argus
IBM upgraded to Buy from Hold at Argus
PPG PPG
$134.67 /

-2.555 (-1.86%)

10/19/20 Truist
Truist raises price targets in select Chemicals names
10/09/20 Deutsche Bank
PPG price target raised to $150 from $135 at Deutsche Bank
10/09/20 Citi
Westlake Chemical upgraded to Buy from Neutral at Citi
09/22/20 Evercore ISI
PPG initiated with an In Line at Evercore ISI
PHR Phreesia
$32.30 /

-0.43 (-1.31%)

09/22/20 DA Davidson
Phreesia initiated with a Buy at DA Davidson
09/22/20 DA Davidson
Phreesia initiated with a Buy at DA Davidson
09/09/20 Piper Sandler
Phreesia price target raised to $35 from $34 at Piper Sandler
07/14/20 Citi
Phreesia initiated with a Neutral at Citi
BLU Bellus Health
$2.32 /

-0.07 (-2.94%)

08/14/20 H.C. Wainwright
Bellus Health price target lowered to $10 from $28 at H.C. Wainwright
07/07/20 Guggenheim
Guggenheim downgrades Bellus Health to Neutral after 'disappointing' cough trial
07/07/20 Guggenheim
Bellus Health downgraded to Neutral from Buy at Guggenheim
07/06/20 Jefferies
Jefferies cuts Bellus target to $6, sees potential for 'meaningful upside'
ZION Zions Bancorp
$30.22 /

-0.92 (-2.95%)

SPNE SeaSpine
$14.97 /

-0.42 (-2.73%)

PPG PPG
$134.67 /

-2.555 (-1.86%)

PHR Phreesia
$32.30 /

-0.43 (-1.31%)

IBM IBM
$125.53 /

-0.4 (-0.32%)

HXL Hexcel
$36.30 /

+0.73 (+2.05%)

ELS Equity Lifestyle
$63.05 /

-0.88 (-1.38%)

CCK Crown Holdings
$82.17 /

-1.115 (-1.34%)

ATEC Alphatec
$9.88 /

-0.23 (-2.27%)

APTX Aptinyx
$3.64 /

-0.1 (-2.67%)

ACOR Acorda Therapeutics
$0.69 /

+0.0214 (+3.19%)

  • 21
    Oct
  • 20
    Oct
  • 14
    Oct
  • 10
    Jul
  • 10
    Jan
  • 08
    Jan
  • 13
    Dec
PPG PPG
$134.67 /

-2.555 (-1.86%)

IBM IBM
$125.53 /

-0.4 (-0.32%)

CCK Crown Holdings
$82.17 /

-1.115 (-1.34%)

PPG PPG
$134.67 /

-2.555 (-1.86%)

PHR Phreesia
$32.30 /

-0.43 (-1.31%)

IVA Inventiva
$14.70 /

+0.41 (+2.87%)

IBM IBM
$125.53 /

-0.4 (-0.32%)

HXL Hexcel
$36.30 /

+0.73 (+2.05%)

CCK Crown Holdings
$82.17 /

-1.115 (-1.34%)

BLU Bellus Health
$2.32 /

-0.07 (-2.94%)

ATEC Alphatec
$9.88 /

-0.23 (-2.27%)

ZION Zions Bancorp
$30.22 /

-0.92 (-2.95%)

PPG PPG
$134.67 /

-2.555 (-1.86%)

PHR Phreesia
$32.30 /

-0.43 (-1.31%)

IBM IBM
$125.53 /

-0.4 (-0.32%)

ACOR Acorda Therapeutics
$0.69 /

+0.0214 (+3.19%)

Hot Stocks
Inventiva gets FDA fast track designation in MPS VI for clinical stage odiparcil » 16:06
10/19/20
10/19
16:06
10/19/20
16:06
IVA

Inventiva

$14.70 /

+0.41 (+2.87%)

Inventiva announced that…

Inventiva announced that the U.S. Food and Drug Administration, FDA, has granted Fast Track designation to odiparcil, the Company's clinical-stage drug candidate for the treatment of MPS type VI, MPS VI, a rare and progressive genetic disorder. The Fast Track program of the FDA is designed to facilitate the development and expedite the regulatory review and potential approval of drug candidates. Its overall objective is to improve patient access to therapies aimed at treating serious conditions and filling significant unmet medical needs. Pierre Broqua, Ph.D., Chief Scientific Officer and cofounder of Inventiva, commented: "We are very pleased by the FDA's decision to grant Fast Track designation to odiparcil for the treatment of MPS VI. It is a clear recognition of the existing unmet medical need for this rare and progressive genetic disorder. We believe that odiparcil has the potential to become a treatment of choice for MPS VI patients, especially due to its oral formulation and ability to reach organs and tissues which are poorly treated by the current standard of care. This designation represents an important step in the development of odiparcil towards becoming an additional treatment for MPS VI patients, who are looking for more efficacious and convenient therapies."

ShowHide Related Items >><<
IVA Inventiva
$14.70 /

+0.41 (+2.87%)

IVA Inventiva
$14.70 /

+0.41 (+2.87%)

10/13/20 Roth Capital
Roth backs Buy on Inventiva after Lanifibranor given breakthrough designation
08/17/20 H.C. Wainwright
Inventiva price target raised to $38 from EUR 12 at H.C. Wainwright
08/05/20
Fly Intel: Top five analyst initiations
08/05/20 Roth Capital
Inventiva initiated with a Buy at Roth Capital
  • 10
    Jul
IVA Inventiva
$14.70 /

+0.41 (+2.87%)

Over a week ago
Recommendations
Roth backs Buy on Inventiva after Lanifibranor given breakthrough designation » 11:08
10/13/20
10/13
11:08
10/13/20
11:08
IVA

Inventiva

$14.37 /

+0.86 (+6.37%)

Roth Capital analyst…

Roth Capital analyst Zegbeh Jallah reiterated a Buy rating and EUR 32 price target on Inventiva following the announcement that the company received a Breakthrough Designation for its lead drug, Lanifibranor being developed for NASH, after Lanifibranor's Phase 2b study met both primary and secondary endpoints. The analyst sees the Breakthrough Designation as "a sign the FDA is likely not changing the NASH goal-post, which is a positive ahead of Inventiva's upcoming End-of-Phase 2 meeting."

ShowHide Related Items >><<
IVA Inventiva
$14.37 /

+0.86 (+6.37%)

IVA Inventiva
$14.37 /

+0.86 (+6.37%)

08/17/20 H.C. Wainwright
Inventiva price target raised to $38 from EUR 12 at H.C. Wainwright
08/05/20
Fly Intel: Top five analyst initiations
08/05/20 Roth Capital
Inventiva initiated with a Buy at Roth Capital
08/04/20
Fly Intel: Top five analyst initiations
  • 10
    Jul
IVA Inventiva
$14.37 /

+0.86 (+6.37%)

On The Fly
Fly Intel: After-Hours Movers » 18:32
10/12/20
10/12
18:32
10/12/20
18:32
ETH

Ethan Allen

$15.63 /

+0.14 (+0.90%)

, IVA

Inventiva

$13.51 /

+0.26 (+1.96%)

, EXC

Exelon

$39.98 /

+0.78 (+1.99%)

, DIS

Disney

$124.97 /

+0.01 (+0.01%)

, SRNE

Sorrento Therapeutics

$11.41 /

+0.13 (+1.15%)

, DPHC

DiamondPeak Holdings

$25.15 /

+2.12 (+9.21%)

, MU

Micron

$50.67 /

+0.79 (+1.58%)

, WSM

Williams-Sonoma

$99.78 /

-0.34 (-0.34%)

, VYGR

Voyager Therapeutics

$12.02 /

+0.47 (+4.07%)

Check out this evening's…

ShowHide Related Items >><<
WSM Williams-Sonoma
$99.78 /

-0.34 (-0.34%)

VYGR Voyager Therapeutics
$12.02 /

+0.47 (+4.07%)

SRNE Sorrento Therapeutics
$11.41 /

+0.13 (+1.15%)

MU Micron
$50.67 /

+0.79 (+1.58%)

IVA Inventiva
$13.51 /

+0.26 (+1.96%)

EXC Exelon
$39.98 /

+0.78 (+1.99%)

ETH Ethan Allen
$15.63 /

+0.14 (+0.90%)

DPHC DiamondPeak Holdings
$25.15 /

+2.12 (+9.21%)

DIS Disney
$124.97 /

+0.01 (+0.01%)

ETH Ethan Allen
$15.63 /

+0.14 (+0.90%)

IVA Inventiva
$13.51 /

+0.26 (+1.96%)

08/17/20 H.C. Wainwright
Inventiva price target raised to $38 from EUR 12 at H.C. Wainwright
08/05/20
Fly Intel: Top five analyst initiations
08/05/20 Roth Capital
Inventiva initiated with a Buy at Roth Capital
08/04/20
Fly Intel: Top five analyst initiations
EXC Exelon
$39.98 /

+0.78 (+1.99%)

08/24/20 Morgan Stanley
Morgan Stanley says Illinois Governor's energy principles positive for Exelon
08/17/20
Fly Intel: Top five analyst downgrades
08/17/20 BofA
Exelon downgraded to Underperform from Neutral at BofA
08/17/20 BofA
Exelon downgraded to Underperform from Neutral at BofA
DIS Disney
$124.97 /

+0.01 (+0.01%)

10/06/20 Piper Sandler
Netflix remains top video platform among teens, says Piper Sandler
10/02/20 JPMorgan
Disney price target raised to $155 from $135 at JPMorgan
10/01/20 MoffettNathanson
Disney price target raised to $136 from $118 at MoffettNathanson
10/01/20 Citi
Disney layoffs represent 13% of total employee base, says Citi
SRNE Sorrento Therapeutics
$11.41 /

+0.13 (+1.15%)

07/31/20 H.C. Wainwright
Sorrento Therapeutics price target raised to $30 from $24 at H.C. Wainwright
07/20/20 Dawson James
Sorrento antibody cocktail effort could move quickly, says Dawson James
05/26/20 Dawson James
Sorrento Therapeutics initiated with a Buy at Dawson James
DPHC DiamondPeak Holdings
$25.15 /

+2.12 (+9.21%)

10/12/20 BTIG
DiamondPeak Holdings initiated with a Buy at BTIG
09/18/20 Colliers
Lordstown's presentation raised Colliers' expectations for Workhorse valuation
09/17/20 Roth Capital
Roth raises Workhorse target to $33 after Lordstown's 'compelling' analyst day
09/03/20 Oppenheimer
Oppenheimer bullish on Workhorse Group, initiates with an Outperform
MU Micron
$50.67 /

+0.79 (+1.58%)

10/12/20 Deutsche Bank
Micron upgraded to Buy from Hold at Deutsche Bank
10/12/20 Deutsche Bank
Micron upgraded to Buy from Hold at Deutsche Bank
09/30/20 Needham
Micron price target lowered to $65 from $70 at Needham
09/30/20 JPMorgan
JPMorgan sees 'good opportunity' to get long Micron shares
WSM Williams-Sonoma
$99.78 /

-0.34 (-0.34%)

08/27/20 Wedbush
Williams-Sonoma price target raised to $115 from $105 at Wedbush
08/27/20 Loop Capital
Williams-Sonoma price target raised to $100 from $80 at Loop Capital
08/25/20 RBC Capital
Williams-Sonoma price target raised to $99 from $76 at RBC Capital
08/24/20 JPMorgan
Williams-Sonoma price target raised to $89 from $75 at JPMorgan
VYGR Voyager Therapeutics
$12.02 /

+0.47 (+4.07%)

08/05/20 Benchmark
Voyager 'break up' with AbbVie has no impact on valuation, says Benchmark
08/04/20 H.C. Wainwright
Voyager Therapeutics price target lowered to $14 from $18 at H.C. Wainwright
03/30/20 Nomura
Voyager Therapeutics price target lowered to $16 from $37 at Nomura Instinet
03/19/20
Fly Intel: Top five analyst initiations
WSM Williams-Sonoma
$99.78 /

-0.34 (-0.34%)

VYGR Voyager Therapeutics
$12.02 /

+0.47 (+4.07%)

MU Micron
$50.67 /

+0.79 (+1.58%)

EXC Exelon
$39.98 /

+0.78 (+1.99%)

ETH Ethan Allen
$15.63 /

+0.14 (+0.90%)

DIS Disney
$124.97 /

+0.01 (+0.01%)

  • 10
    Jul
WSM Williams-Sonoma
$99.78 /

-0.34 (-0.34%)

SRNE Sorrento Therapeutics
$11.41 /

+0.13 (+1.15%)

MU Micron
$50.67 /

+0.79 (+1.58%)

EXC Exelon
$39.98 /

+0.78 (+1.99%)

DPHC DiamondPeak Holdings
$25.15 /

+2.12 (+9.21%)

DIS Disney
$124.97 /

+0.01 (+0.01%)

WSM Williams-Sonoma
$99.78 /

-0.34 (-0.34%)

SRNE Sorrento Therapeutics
$11.41 /

+0.13 (+1.15%)

MU Micron
$50.67 /

+0.79 (+1.58%)

EXC Exelon
$39.98 /

+0.78 (+1.99%)

DPHC DiamondPeak Holdings
$25.15 /

+2.12 (+9.21%)

DIS Disney
$124.97 /

+0.01 (+0.01%)

WSM Williams-Sonoma
$99.78 /

-0.34 (-0.34%)

SRNE Sorrento Therapeutics
$11.41 /

+0.13 (+1.15%)

MU Micron
$50.67 /

+0.79 (+1.58%)

EXC Exelon
$39.98 /

+0.78 (+1.99%)

DPHC DiamondPeak Holdings
$25.15 /

+2.12 (+9.21%)

DIS Disney
$124.97 /

+0.01 (+0.01%)

Hot Stocks
Inventiva receives breakthrough therapy designation for lanifibranor from FDA » 16:02
10/12/20
10/12
16:02
10/12/20
16:02
IVA

Inventiva

$13.51 /

+0.26 (+1.96%)

Inventiva announced that…

Inventiva announced that the FDA has granted breakthrough therapy designation to lanifibranor, the company's lead drug candidate, for the treatment of NASH. The company said lanifibranor is believed to be the first drug candidate to be granted this status for the treatment of NASH since January 2015.

ShowHide Related Items >><<
IVA Inventiva
$13.51 /

+0.26 (+1.96%)

08/17/20 H.C. Wainwright
Inventiva price target raised to $38 from EUR 12 at H.C. Wainwright
08/05/20
Fly Intel: Top five analyst initiations
08/05/20 Roth Capital
Inventiva initiated with a Buy at Roth Capital
08/04/20
Fly Intel: Top five analyst initiations
  • 10
    Jul
Over a month ago
Conference/Events
Inventiva participates in a webinar with Roth Capital » 11:25
09/21/20
09/21
11:25
09/21/20
11:25
IVA

Inventiva

$11.42 /

-0.115 (-1.00%)

Biotech Analyst Jallah…

Biotech Analyst Jallah holds a webinar with management on September 21 at 12 pm hosted by Roth Capital. Webcast Link

ShowHide Related Items >><<
IVA Inventiva
$11.42 /

-0.115 (-1.00%)

08/17/20 H.C. Wainwright
Inventiva price target raised to $38 from EUR 12 at H.C. Wainwright
08/05/20
Fly Intel: Top five analyst initiations
08/05/20 Roth Capital
Inventiva initiated with a Buy at Roth Capital
08/04/20
Fly Intel: Top five analyst initiations
  • 10
    Jul
Conference/Events
Inventiva participates in a webinar with Roth Capital » 04:55
09/21/20
09/21
04:55
09/21/20
04:55
IVA

Inventiva

$11.62 /

-0.48 (-3.97%)

Biotech Analyst Jallah…

Biotech Analyst Jallah holds a webinar with management on September 21 at 12 pm hosted by Roth Capital. Webcast Link

ShowHide Related Items >><<
IVA Inventiva
$11.62 /

-0.48 (-3.97%)

08/17/20 H.C. Wainwright
Inventiva price target raised to $38 from EUR 12 at H.C. Wainwright
08/05/20
Fly Intel: Top five analyst initiations
08/05/20 Roth Capital
Inventiva initiated with a Buy at Roth Capital
08/04/20
Fly Intel: Top five analyst initiations
  • 10
    Jul
Conference/Events
Inventiva participates in a webinar with Roth Capital » 11:31
09/14/20
09/14
11:31
09/14/20
11:31
IVA

Inventiva

$11.68 /

+ (+0.00%)

Biotech Analyst Jallah…

Biotech Analyst Jallah holds a webinar with management on September 21 at 12 pm hosted by Roth Capital. Webcast Link

ShowHide Related Items >><<
IVA Inventiva
$11.68 /

+ (+0.00%)

08/17/20 H.C. Wainwright
Inventiva price target raised to $38 from EUR 12 at H.C. Wainwright
08/05/20
Fly Intel: Top five analyst initiations
08/05/20 Roth Capital
Inventiva initiated with a Buy at Roth Capital
08/04/20
Fly Intel: Top five analyst initiations
  • 10
    Jul
Recommendations
Inventiva price target raised to $38 from EUR 12 at H.C. Wainwright » 06:15
08/17/20
08/17
06:15
08/17/20
06:15
IVA

Inventiva

$11.74 /

+0.06 (+0.51%)

H.C. Wainwright analyst…

H.C. Wainwright analyst Ed Arce raised the firm's price target on Inventiva to $38 from EUR 12 and reiterates a Buy rating on the shares. The Phase 2b NATIVE study results "sets a new precedent in NASH," Arce tells investors in a research note. The analyst views Inventiva shares as "deeply undervalued."

ShowHide Related Items >><<
IVA Inventiva
$11.74 /

+0.06 (+0.51%)

08/05/20
Fly Intel: Top five analyst initiations
08/05/20 Roth Capital
Inventiva initiated with a Buy at Roth Capital
08/04/20
Fly Intel: Top five analyst initiations
08/04/20 Guggenheim
Guggenheim starts 'underappreciated' Inventiva at Buy with $26 price target
  • 10
    Jul
Initiation
Fly Intel: Top five analyst initiations » 10:16
08/05/20
08/05
10:16
08/05/20
10:16
EAT

Brinker

$28.65 /

+1.02 (+3.69%)

, PHIO

Phio Pharmaceuticals

$2.62 /

+0.01 (+0.38%)

, IVA

Inventiva

$11.10 /

+0.34 (+3.16%)

, BEAM

Beam Therapeutics

$19.88 /

+0.45 (+2.32%)

, MITFF

Mitie Group

$0.00 /

+ (+0.00%)

Catch up on today's…

Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Brinker (EAT) initiated with a Buy at Jefferies. 2. Phio Pharmaceuticals (PHIO) initiated with a Buy at H.C. Wainwright. 3. Inventiva (IVA) initiated with a Buy at Roth Capital. 4. Beam Therapeutics (BEAM) initiated with an Outperform at William Blair. 5. Mitie Group (MITFF) initiated with a Neutral at JPMorgan. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.

ShowHide Related Items >><<
PHIO Phio Pharmaceuticals
$2.62 /

+0.01 (+0.38%)

EAT Brinker
$28.65 /

+1.02 (+3.69%)

BEAM Beam Therapeutics
$19.88 /

+0.45 (+2.32%)

EAT Brinker
$28.65 /

+1.02 (+3.69%)

08/05/20 Jefferies
Brinker initiated with a Buy at Jefferies
07/01/20 Gordon Haskett
Brinker downgraded to Hold as reopenings pause at Gordon Haskett
07/01/20 Gordon Haskett
Brinker downgraded to Hold from Buy at Gordon Haskett
06/29/20 Stifel
Stifel says Brinker appears to have created new wing chain 'virtually overnight'
PHIO Phio Pharmaceuticals
$2.62 /

+0.01 (+0.38%)

08/05/20 H.C. Wainwright
Phio Pharmaceuticals initiated with a Buy at H.C. Wainwright
IVA Inventiva
$11.10 /

+0.34 (+3.16%)

08/05/20 Roth Capital
Inventiva initiated with a Buy at Roth Capital
08/04/20
Fly Intel: Top five analyst initiations
08/04/20 Guggenheim
Guggenheim starts 'underappreciated' Inventiva at Buy with $26 price target
08/04/20 Stifel
Inventiva initiated with a Buy at Stifel
BEAM Beam Therapeutics
$19.88 /

+0.45 (+2.32%)

08/05/20 William Blair
Beam Therapeutics initiated with an Outperform at William Blair
03/02/20
Fly Intel: Top five analyst initiations
03/02/20 Wedbush
Wedbush bullish on Beam Therapeutics, initiates with an Outperform
03/02/20 JPMorgan
Beam Therapeutics initiated with an Overweight at JPMorgan
MITFF Mitie Group
$0.00 /

+ (+0.00%)

08/05/20 JPMorgan
Mitie Group initiated with a Neutral at JPMorgan
08/03/20 Jefferies
Mitie Group upgraded to Buy from Hold at Jefferies
EAT Brinker
$28.65 /

+1.02 (+3.69%)

BEAM Beam Therapeutics
$19.88 /

+0.45 (+2.32%)

  • 10
    Jul
  • 07
    May
  • 06
    Feb
EAT Brinker
$28.65 /

+1.02 (+3.69%)

BEAM Beam Therapeutics
$19.88 /

+0.45 (+2.32%)

EAT Brinker
$28.65 /

+1.02 (+3.69%)

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.